Mateon Therapeutics, Inc. (MATN) Starts Presentation at the 2017 Marcum Microcap Conference
Mateon Therapeutics (OTC: MATN) is a biopharmaceutical company focused on vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents(AAs), which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. The company believes it can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to central tumor cell death while AAs prevent formation of new tumor blood vessels. For more information, visit…